$NVO Semaglutide in NASH P2 ve for all 3 doses. Resolution of NASH no worsening in fibrosis 59% for high dose vs 17% for placebo @ 72 wks. Comparatively $NGM FGF19 @ WK 24 24% vs 9% $ICPT$MDGL$VKTX$AKRO
Moderna and @LonzaPB announce worldwide strategic collaboration to manufacture Moderna's #vaccine (mRNA-1273) against novel coronavirus. Read more: buff.ly/2Yn8LtG#mRNA
#Breaking: Pivotal data evaluating spinal muscular atrophy (SMA) medicine shows study met its primary endpoint in infants with Type 1 #SMA. gene.com/media/press-release…
$AZN$MRK Lynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer astrazeneca.com/media-centre…
$PSTI Secures €50M Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III Studies globenewswire.com/news-relea…